According to a phase I/II trial, analyzing the safety and efficacy of brigatinib in a patient cohort with late-stage malignant disease, among them ALK-positive NSCLC, patients were sub-divided into five treatment groups [66]: First, ALK inhibitor-naïve patients with ALK-positive NSCLC;second, crizotinib-pre-treated ALK-positive NSCLC; third, EGFR T790M-positive NSCLC with EGFR-TKI resistance; fourth, patients suffering from other cancer entities; and fifth, NSCLC patients with CNS metastases, either crizotinib-naïve or post crizotinib. Here, ALK is linked to non-small cell lung carcinoma.